20 March 2008

Appointment of New Chairman

Cyprotex PLC (LSE:CRX), the drug discovery services and information group, announces that its Non-Executive Director, Mr. Nikolas Sofronis, will assume a new role as Non-Executive Chairman of Cyprotex PLC from 1st April 2008.

The role of Executive Chairman was previously held by Mr. Robert Morrisson Atwater, who at the same time also carried out the role Cyprotex's Chief Executive Officer. After 1st April 2008, Mr. Robert Morrisson Atwater will continue the single role of Chief Executive Officer.

Mr. Robert Morrisson Atwater commented: 'As Cyprotex expands, so do pressures on the role of the Chief Executive Officer. Bearing this in mind, and the Group's wish to comply with best practice and maintain high standards of corporate governance, I believe Nikolas Sofronis to be an excellent candidate for this responsible role. I look forward to working with him.'

Mr. Nikolas Sofronis commented: 'I look forward to actively fulfilling the role of Non-Executive Chairman for Cyprotex. The Group's potential has yet to be fully realised. I look forward to taking a more significant role in helping to steer the Group while also championing the interests of shareholders.'

Nikolas Sofronis (age 43 years), having graduated from the Athens Bar, is a lawyer by training. For the past 17 years, he has worked in numerous high profile asset management organisations. While working for HSBC, Credit Lyonnais, Republic Bank of New York, Paribas SA, amongst other, he has developed a broad base of contacts within European pharmaceutical and biotechnology companies.

For further information:
Cyprotex PLC
Robert Morrisson Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Media Enquires:
WMC Communications
Simon Miller
Tel: +44 (0)20 7930 9030
simon.miller@wmccommunications.com